Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Last updated: February 27, 2026 10:11 am

By Weekly Voice editorial staff

Share

0 Min Read